

## EC PULMONOLOGY AND RESPIRATORY MEDICINE Letter to Editor

## Does Smoking Decrease the Susceptibility for SARS-CoV-2?

## Agnes Schubert-Tennigkeit\*

Novartis Pharma AG, Switzerland

\*Corresponding Author: Agnes Schubert-Tennigkeit, Novartis Pharma AG, Switzerland. E-mail: tennigkeit@hotmail.com

Received: May 08, 2020; Published: August 05, 2020

Binding to angiotensin-converting enzyme-2 receptor (ACE2) is the key entry mechanism for SARS-CoV-2 to enter the lung tissue. Consequently, blocking ACE2 receptor in the lung could prevent SARS-CoV-2 entry. Nicotine has been found to downregulate ACE2 receptors in smokers [1]. Hence smokers may be less susceptible for COVID-2 infection.

To investigate this hypothesis, I reviewed the rates of smokers and/or patients with COPD as concomitant disease in SARS-CoV-2 hospitalized patients and put them into perspective with the prevalence of smoking in the general population.

Authors	Setting	Sample size	Smoker/COPD	Non-smoker
Guan., et al. [2]	China	1099	12.6%	85.4%
Guan., et al. [3]	China	1590	1.5%	
Zhou., et al. [4]	China	191	3%	
Zhang., et al. [5]	China	140	1.4%	
Shi., et al. [9]	China	487	8.2%	89.1%

Table 1: Characteristics of the cohorts included.

Low rates of smokers within these hospitalized cohorts are surprising, since China has one of the highest prevalence of smoking worldwide [6]. In 2010, China had the highest male smoking prevalence only after Russia [10]. Other Asian countries have comparatively high rates: South Korea 50%, Taiwan 34%, Japan ~40%, whereas the prevalence for smoking in Europe and the U.S is much lower [10].

The new SARS-CoV-2 virus has a higher affinity for ACE2 compared with the prior SARS-CoV. ACE2 receptors are predominantly expressed by bronchial and alveolar epithelial cells in the lung. Nicotine has been shown to increase the expression and/or activity of renin, ACE and AT1R, whereas in the compensatory ACE2/ANG-(1-7)/MasR arm, nicotine downregulates the expression and/or activity of ACE2 and AT2R [1]. Chronic downregulation may have contributed to a relatively lower infection rate of active smokers, despite their general higher risk for lung infections, respiratory distress and concomitant cardiovascular disease. A recent manuscript warns over ACE inhibitors and angiotensin receptors blockers increasing the severity of COVID-19 by upregulation of ACE2 receptors in the respiratory tract [7]. Based on preliminary meta-analysis on Chinese patients, smokers appear not to have a significantly increased risk of progressing towards severe COVID-19 infection [8].

In conclusion, smokers may have a potential lower susceptibility for COVID-19 infection via the ACE2 downregulation. Further epidemiological studies need to confirm this hypothesis.

## **Bibliography**

- 1. Oakes JM., et al. "Nicotine and the renin-angiotensin system". The American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 315.5 (2018): R895-R906.
- 2. Guan WJ., et al. "Clinical Characteristics of Coronavirus Disease 2019 in China". The New England Journal of Medicine (2020).
- 3. Guan WJ., et al. "Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis". The European Respiratory Journal 55.5 (2020): 2000547.
- 4. Zhou F, *et al.* "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study". *Lancet* 395.10229 (2020): 1054-1062.
- 5. Zhang JJ., et al. "Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China". Allergy 75.7 (2020): 1730-1741.
- 6. Wang N., et al. "[Survey of smoking prevalence in adults aged 40 years and older in China, 2014]". Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi 39.5 (2018): 551-556.
- Diaz JH. "Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19". Journal of Travel Medicine (2020).
- 8. Lippi G and Henry BM. "Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19)". *European Journal of Internal Medicine* 75 (2020): 107-108.
- 9. Shi Y., et al. "Host susceptibility to severe COVID-19 and establishment of a host risk score findings of 487 cases outside Wuhan". Critical Care 24 (2020): 108.
- 10. Giovino GA., *et al.* "Asma S for The GATS Collaborative Group. Tobacco use in 3 billion individuals from 16 countries: an analysis of national representative cross-sectional household surveys". *Lancet* 380 (2012): 668-679.

Volume 9 Issue 9 September 2020 ©All rights reserved by Agnes Schubert-Tennigkeit.